New treatment for chronic obstructive pulmonary disease
Olodaterol, a once-daily long acting β2-agonist inhaler, has been launched in the UK for chronic obstructive pulmonary disease.
Olodaterol, a once-daily long acting beta2 agonist (LABA) inhaler, has been launched in the UK as an additional treatment option for chronic obstructive pulmonary disease (COPD).
The treatment is indicated as a maintenance bronchodilator treatment in patients with COPD. Improvement in lung function is comparable to formoterol and tiotropium, according to the summary of product characteristics.
“For people with mild or moderate COPD who remain breathless despite short-acting bronchodilators and who are not having frequent exacerbations, the LABAs offer an [equally] as effective alternative to the long-acting muscarinic antagonists such as tiotropium,” says Anna Murphy, consultant respiratory pharmacist at University Hospitals of Leicester NHS Trust.
A number of LABAs used for COPD already exist on the market, including formoterol, indacterol and vilanterol.
It is essential to confirm a diagnosis of COPD prior to starting LABA treatment without an inhaled corticosteroid because, for asthmatic patients, this regimen carries an increased risk of death, she added.
The most common adverse events associated with olodaterol include nasopharyngitis, dizziness, hypertension, rash and arthralgia.
Olodaterol is being marketed by Boehringer Ingelheim as Striverdi Respimat. The company is also seeking marketing approval for a once-daily fixed-dose combination inhaler of olodaterol plus tiotropium as a maintenance treatment for patients with COPD.
|Factfile: Product details|
|Action: long acting beta2 agonist|
|Dose: 5mg per day taken as two puffs via an inhaler once daily|
|Legal category: Prescription only medicine|
|NHS list price: one inhaler and 60 puff cartridge (30 doses) £26.35|
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065976
Recommended from Pharmaceutical Press